Johnson & Johnson’s VP sells shares worth $1.16 million

Johnson & Johnson (NYSE:JNJ) recently saw a significant transaction involving its VP Corporate Controller, Robert J. Decker. On February 25, 2025, Decker sold 6,999 shares of the company’s common stock at an average price of $165.88 per share, resulting in a total sale value of approximately $1.16 million.

This sale followed the exercise of employee stock options, where Decker acquired the same number of shares at a price of $101.87 each, totaling approximately $712,988. After these transactions, Decker holds 21,001 shares directly.

In addition to his direct holdings, Decker also has indirect ownership through a 401k and an ESOP, holding 620 and 134 shares, respectively. These holdings reflect shares accrued through dividend reinvestment and savings plans as of the most recent reporting date.

In other recent news, Johnson & Johnson has completed a significant capital raise through a multi-billion euro public offering of notes, according to a recent SEC filing. The offering includes various notes with maturity dates ranging from 2029 to 2055 and interest rates between 2.700% and 3.700%. Additionally, Johnson & Johnson announced the issuance of $5 billion in new notes, with varying maturity dates and interest rates, as part of its capital management strategy. The company plans to use the funds for general corporate purposes, including refinancing existing debt and potential acquisitions.

In related developments, S&P Global Ratings assigned an ’AAA’ rating to Johnson & Johnson’s new senior unsecured notes but placed them on CreditWatch with negative implications due to the planned acquisition of Intra-Cellular Therapies (NASDAQ:ITCI) Inc. for approximately $14.6 billion. This acquisition is expected to increase the company’s adjusted leverage, although it is anticipated to decline over the next few years. In the healthcare sector, Johnson & Johnson is noted by BTIG’s Jonathan Krinsky as nearing a breakout, indicating potential growth. Furthermore, the company’s drug TREMFYA® has shown promising results in a Phase 3 study for treating ulcerative colitis, with significant improvements in clinical measures compared to placebo.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.